US FDA Reverses Course on Autism Treatment & Approves Leucovorine for Rare Genetic Condition

The U.S. Food and Drug Administration is recalibrating its approach to potential treatments for autism spectrum disorder, specifically focusing on cerebral folate deficiency (CFD), a rare genetic condition sometimes associated with autistic features. This shift, initially announced in September 2025, involves broadening the approved employ of leucovorin calcium, a generic drug, but has also drawn scrutiny regarding the speed of the process and the scope of the approval. The move comes as the FDA acknowledges a fourfold increase in autism diagnoses over the past two decades, prompting a search for viable treatment options.

Leucovorin and Cerebral Folate Deficiency: A Targeted Approach

The FDA’s action doesn’t represent a broad approval of leucovorin as a universal autism treatment. Instead, the agency is focusing on patients diagnosed with CFD, a neurological condition impacting the transport of folate – a crucial B vitamin – into the brain. Individuals with CFD often exhibit developmental delays alongside symptoms commonly associated with autism, including challenges with social communication, sensory processing, and repetitive behaviors. The FDA’s decision is based on a systematic analysis of literature published between 2009 and 2024, encompassing case reports and mechanistic data supporting leucovorin’s potential benefit for those with CFD.

Leucovorin, also known as folinic acid, is typically used to mitigate the side effects of methotrexate, a chemotherapy drug. Its function is to provide a readily usable form of folate, bypassing the metabolic block present in individuals with CFD. As Dr. David Mandell, a professor of psychiatry at the University of Pennsylvania Perelman School of Medicine, explained in The Guardian, leucovorin is “very similar to folic acid” but is altered to more easily cross the blood-brain barrier in those who struggle to metabolize folic acid.

A Faster Track and Concerns from the Medical Community

The FDA’s decision to expedite the approval process has raised eyebrows among some health experts. The typical FDA approval pathway is lengthy and rigorous, involving extensive clinical trials. Although, the agency, under Commissioner Marty Makary, has indicated a willingness to explore repurposing existing drugs to address chronic diseases, citing a need to deliver potential treatments to those who are suffering. This approach, while potentially faster, has prompted concerns about the level of evidence supporting leucovorin’s efficacy.

Danielle Hall, director of health equity at the Autism Society of America, cautioned against premature claims, stating that current studies on high-dose leucovorin are “very preliminary.” She warned that such claims could lead to “false hope” and a misinterpretation that leucovorin represents a “cure,” as reported by The Guardian. The FDA acknowledges this concern and is working with GSK, the manufacturer of Wellcovorin (leucovorin calcium), to refine the drug’s labeling to specifically address its use in treating CFD.

GSK’s Role and the Relabeling Process

GSK, as the Recent Drug Application (NDA) holder for Wellcovorin, has preliminarily agreed to collaborate with the FDA on the relabeling effort. This process will involve incorporating essential scientific information regarding the safe and effective use of the drug for both adult and pediatric patients with CFD. The FDA’s Center for Drug Evaluation and Research, led by George Tidmarsh, M.D., Ph.D., emphasized the agency’s commitment to identifying opportunities to repurpose drugs for chronic diseases, as detailed in the FDA press release.

Financial Implications and Market Dynamics

While the financial implications of this relabeling are not yet fully clear, the expanded use of leucovorin could lead to increased demand for the drug. Leucovorin is a generic medication, meaning it is generally less expensive than brand-name drugs. However, increased demand could potentially impact pricing and supply chains. GSK’s role in the relabeling process and potential manufacturing capacity will be key factors in determining the drug’s availability, and cost. The Forbes report highlights that the FDA is also exploring the potential of leucovorin for autistic children with speech issues, which could further broaden the market.

Beyond Leucovorin: The FDA’s Broader Commitment

The FDA’s decision regarding leucovorin is part of a broader effort to address the rising prevalence of autism and to find effective treatments for individuals with the condition. Commissioner Makary stated that the agency remains “committed to finding and treating the root causes of autism.” This commitment suggests that the FDA may continue to explore alternative treatment options and to streamline the approval process for promising therapies, particularly those targeting underlying biological mechanisms. However, the agency’s approach will likely continue to be met with scrutiny from the medical community, emphasizing the need for rigorous scientific evidence and transparent communication.

What’s Next: Implementation and Ongoing Research

The immediate next step involves GSK finalizing the relabeling of Wellcovorin to reflect the FDA’s expanded approval for CFD. This process will require submitting updated information to the agency and obtaining final approval. Following the relabeling, healthcare providers will be able to prescribe leucovorin for patients diagnosed with CFD, potentially offering a new treatment option for those who have previously had limited choices.

Concurrently, ongoing research will be crucial to further evaluate the efficacy of leucovorin and to identify other potential treatments for autism. The FDA’s commitment to identifying the root causes of autism suggests that future research efforts will focus on understanding the complex biological mechanisms underlying the condition and developing targeted therapies. The agency’s willingness to consider repurposing existing drugs, as demonstrated with leucovorin, could accelerate the development of new treatments and provide hope for individuals and families affected by autism.